empower pharmacy lawsuit semaglutide update Novo Nordisk expands lawsuits against weight-loss drug compounders As GLP-1 weight-loss drugs surged
Description
Vanhanen, J
The SURPASS 2 trial was a head-to-head comparison with one of the most effective GLP-1 analogues, semaglutide, in patients only on metformin
2 But as therapeutic use expands, so does our understanding of the complex physiological adaptations these drugs invoke
17 October 2025
The letter did not cite manufacturing, safety, or medication quality problems
Improved insulin sensitivity and reduced muscle fat infiltration also led to better muscle quality, even when total volume decreased slightly
